[1] Burchfield J S, Xie M, Hill J A. Pathological ventricular remodeling: mechanisms: Part 1 of 2 [J]. Circulation, 2013, 128: 388-400.
[2] Borlaug B A, Paulus W J. Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment [J]. European Heart Journal, 2011, 32: 670-679.
[3] Roger V L, Go A S, Lloyd-Jones D M, et al. Heart disease and stroke statistics—2012 update: a report from the American Heart Association [J]. Circulation, 2012, 125: e2-e220.

[4] DeFrances C J, Podgornik M N. 2004 national hospital discharge survey [J]. Advance Data, 2006, 29: 1-19.
[5] Xie M, Burchfield J S, Hill J A. Pathological ventricular remodeling: therapies: Part 2 of 2 [J]. Circulation, 2013, 128: 1021-1030.
[6] Owens A T, Brozena S C, Jessup M. New management strategies in heart failure [J]. Circulation Research, 2016, 118: 480-495.
[7] Suematsu Y, Miura S I, Goto M, et al. LCZ696, an angiotensin receptor-neprilysin inhibitor, improves cardiac function with the attenuation of fibrosis in heart failure with reduced ejection fraction in streptozotocin-induced diabetic mice [J]. European Journal of Heart Failure, 2016, 18: 386-393.
[8] Rosenzweig A. Medicine. Cardiac regeneration [J]. Science, 2012, 338: 1549-1550.
[9] Li X, Zhang J, Huang J, et al. Efficacy and safety of Qili Qiangxin capsules for chronic heart failure study group. A multicenter, randomized, double-blind, parallel-group, placebo-controlled study of the effects of Qili Qiangxin capsules in patients with chronic heart failure [J]. Journal of the American College of Cardiology, 2013, 62: 1065-1072.